{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.81","value":"2208"},{"groupId":"OG001","spread":"29.59","value":"1932"},{"groupId":"OG002","spread":"27.85","value":"2055"},{"groupId":"OG003","spread":"20.33","value":"1709"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.98","value":"167.7"},{"groupId":"OG001","spread":"38.46","value":"129.7"},{"groupId":"OG002","spread":"37.93","value":"146.2"},{"groupId":"OG003","spread":"21.03","value":"113.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: N-desmethyl selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.28","value":"2919"},{"groupId":"OG001","spread":"49.45","value":"2031"},{"groupId":"OG002","spread":"52.12","value":"2450"},{"groupId":"OG003","spread":"32.22","value":"1887"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.54","value":"183.4"},{"groupId":"OG001","spread":"34.30","value":"128.9"},{"groupId":"OG002","spread":"38.80","value":"154.7"},{"groupId":"OG003","spread":"14.86","value":"137.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: N-desmethyl selumetinib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"To further evaluate the PK of the granule formulation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"},{"description":"Japan Cohort (\\>=1 to \\<7 years)","id":"OG003","title":"Japan Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 3, 4, 6, 8, 10-12 and 18-24 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1). Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)","title":"Selumetinib and N-desmethyl Selumetinib AUClast Derived After Single and Multiple Dose Administration","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}